Compare Fastenal Company Common Stock (FAST) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastenal Company Common Stock vs Natera Inc. Common Stock — how do they compare? Fastenal Company Common Stock trades at $52.27 (market cap $59.02B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Fastenal Company Common Stock and Natera Inc. Common Stock are close in size by market cap, and Fastenal Company Common Stock pays a 1.87% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fastenal Company Common Stock for 2 Days and Natera Inc. Common Stock for 0 Days on average.
| FAST | NTRA | |
|---|---|---|
Market Cap | $59.02B | $57.03B |
Volume | 10,054,911 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $52.38 | $425.64 |
52-Week Low | $39.15 | $179.42 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $59.25B | $56.18B |
Dividend Yield | 1.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastenal (FAST) trades at $51.43, down 0.12% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with Q3 2026 earnings of $0.35 per share beating estimates, marking the fourth consecutive quarterly beat. Revenue grew 15.5% year-over-year to $2.46 billion, driven by market share gains and new contract wins. The stock shows resilience with consistent operational performance despite premium valuation metrics.
Outlook remains positive with strong industrial demand and digital initiatives supporting growth, though the elevated P/E ratio of 43.96 presents valuation risk. Analyst consensus leans cautious with 59% hold ratings, suggesting limited near-term upside from current levels. Key risks include economic sensitivity and competitive pressures in industrial distribution.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fastenal Company Common Stock
Fastenal distributes fasteners, tools, safety supplies, and other industrial products. It also provides inventory management and vending solutions for business customers.
Read more on FAST →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
